Treatment of chronic obstructive pulmonary disease (copd)

ABSTRACT

The methods described herein are based on the discovery that the plasma level of a panel of specific proteins differs between two subject populations: 1) subjects at risk for chronic obstructive pulmonary disease (“COPD”) but not manifesting clinical symptoms of COPD; and 2) subjects having very severe COPD. The difference in plasma levels is statistically significant for each protein. The identification of these proteins thus facilitates susceptibility detection, early disease detection, disease severity assessment, disease progression monitoring, and therapy efficacy monitoring.

CROSS-REFERENCE TO RELATED APPLICATION

This is a continuation of U.S. application Ser. No. 14/003,120, filed Oct. 7, 2013, which is the U.S. national phase of International Application PCT/US2012/027998, filed Mar. 7, 2012, which claims the benefit of the filing date of U.S. Provisional Patent Application No. 61/449,879, filed Mar. 7, 2011. The entire disclosures of the aforesaid applications are incorporated herein by reference.

REFERENCE TO GOVERNMENT GRANT

The invention described herein was supported in part by the National Institutes of Health, under grant no. 5RC2HL101713-02. The government has certain rights in this invention.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Mar. 24, 2016 is named 35926_0417_01_US_540632_SL and is 155,918 bytes in size.

BACKGROUND

Chronic obstructive pulmonary disease (COPD) is a chronic lung disease that is incurable and typically progressive. Chronic bronchitis and emphysema are the predominant examples of COPD. Most people diagnosed with COPD have both chronic bronchitis and emphysema. COPD is a leading cause of death worldwide, and its prevalence is increasing in the industrial countries (see, e.g., Lau et al., 2009, J Cell Physiol. 221:535-543; Devanarayan et al., 2010, COPD 7(1):51-58).

Symptoms of COPD include shortness of breath, chronic persistent coughing, chronic coughing that produces excessive amounts of mucus, chest tightness, and wheezing, among other symptoms. On a tissue level, COPD is characterized by inflammation, cell death and extensive lung tissue remodeling. Genetic markers have been studied as potential markers of early disease and prognosis in COPD. See, e.g., Dahl et al., 2009, Internatl J Chron Obstruct Pulmon Dis. 4:157-167. Changes in serum proteins, such as C-reactive protein (CRP) and surfactant proteins A and D, have been identified in COPD patients. See, for instance, Pinto-Plata et al., 2006, Thorax 61(1):23-28; Epub 2005 Sep. 2 and Lau et al., 2009, supra. To date, these changes in serum proteins have not been useful for predicting COPD susceptibility or severity.

Cigarette smoking is the leading risk factor for developing COPD. Other risk factors include cigar smoke, secondhand smoke and air pollution, as well as long term exposure to an excessive amount of dust, chemical fumes, smoke, gases, vapors or mists. Cigarette smoking has been shown to cause up-regulation in the lungs of proteins associated with the unfolded protein response, including GRP78, catreticulin, PDI and CHOP (Kelsen et al., 2008, Am J Respir Cell Mol Biol. 38:541-550; Tagawa et al., 2008 Free Rad Biol Med. 45:50-59). Other biomarkers have been indicated for COPD. See, e.g., U.S. Publication No. 2008/0044843 and WO 2009/114292. While risk factors are known, there is an on-going need to predict reliably which at-risk individuals will develop COPD. In addition, there is a need to predict reliably which COPD patients will experience rapid loss of lung function.

There is an unmet need for methods for assessing susceptibility to COPD development and to assess severity of disease in a COPD patient. The present disclosure addresses this need.

SUMMARY

The following summary is not an extensive overview. It is intended to neither identify key or critical elements of the various embodiments, not delineate the scope of them.

A method for assessing susceptibility of developing chronic obstructive pulmonary disease (COPD) in a subject at risk for developing COPD is disclosed. The method comprises detecting the presence of or assessing the level of at least one biomarker from the group comprising Lethal (3) malignant brain tumor-like 3 protein (LMBL3); Cathelicidin antimicrobial peptide (CAMP); Contactin-1 (CNTN1); Vascular cell adhesion protein 1 (VCAM1); Interleukin-1 receptor accessory protein (IL1RAP); Dermcidin (DCD); Vitamin K-dependent protein Z (PROZ); Hepatocyte growth factor-like (HGFL); Cell surface glycoprotein (MUC18); 79 kDa glucose-regulated protein (GRP78); Coagulation factor V (FA5); Scavenger receptor cysteine-rich type 1 protein M130 (C163A); Neural cell adhesion molecule (NCAM1); Proteoglycan 4 (PRG4); Procollagen C-endopeptidase enhancer 1 (PCOC1); Plastin-2 OS Homo sapiens (PLSL); Coagulation factor XIII A chain (F13A); Fetuin-B (FETUB); Protein 5100-A6 (S10A); Metalloproteinase inhibitor 2 (TIMP2); Peroxiredoxin-1 (PRDX1); Macrophage colony-stimulating factor 1 receptor (CSF1R); Probable G protein coupled receptor 25 (GPR25); Putative zinc-alpha-2-glycoprotein-like 1 (ZAGL1); HLA class I histocompatibility antigen, B-15 alpha chain (1B15); Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA (MA1A1); Myelin P2 (MYP2); Metalloproteinase inhibitor 1 (TIMP1); HLA class I histocompatibility antigen, A-1 alpha chain (1A01); Haptoglobin-alpha isoform 2 (HPT2a); and Haptoglobin-alpha isoform 2 having a post-translational modification (HPT2a-PTM) in the sequence CEADDGCPK (SEQ ID No. 32) comprising at least one of carbamidomethylation of C1, methylation of D4, methylation of D5, and acetylation of K9, in a biological fluid sample obtained from the subject, wherein the biological fluid is selected from peripheral whole blood, serum and plasma. An increased susceptibility of developing COPD is indicated in the at-risk subject if any of the following is determined: a) the presence of one or more of LMBL3, CAMP, CNTN1, VCAM1, IL1RAP, DCD, and PROZ is detected; b) an increased level of one or more of HGFL, MUC18, GRP78, FA5, HPT2a and HPT2a-PTM is assessed, relative to the level of the biomarker in a biological fluid sample from a normal reference; c) a decreased level of one or more of C163A, NCAM1, PRG4, PCOC1, PLSL, F13A, and FETUB is assessed, relative to the level of the biomarker in a biological fluid sample from a normal reference; and/or d) a decreased level of one or more of S10A, TIMP2, PRDX1, CSF1R, GPR25, ZAGL1, 1B15, MA1A1, MYP2, TIMP1, and 1A01 is assessed, relative to the level of the biomarker in a biological fluid sample from a normal reference.

In an embodiment of the method for assessing susceptibility, the biological fluid is plasma or serum.

In an embodiment of the method for assessing susceptibility, the at least one biomarker is selected from HPT2a, GRP78, HGFL, and IL1RAP.

In an embodiment method for assessing susceptibility, at least two or more biomarkers are detected or assessed. In an embodiment, at least one of the at least two biomarker is selected from HPT2a, GRP78, HGFL, and IL1RAP.

In an embodiment of the method for assessing susceptibility, at least three or more biomarkers are detected or assessed. In an embodiment, the at least three or more biomarkers comprise HPT2a, GRP78, HGFL, and IL1RAP.

Also disclosed is a method for assessing severity of COPD in a subject diagnosed with COPD. The method comprises detecting the presence of or assessing the level of a biomarker from the group comprising Lethal (3) malignant brain tumor-like 3 protein (LMBL3); Cathelicidin antimicrobial peptide (CAMP); Contactin-1 (CNTN1); Vascular cell adhesion protein 1 (VCAM1); Interleukin-1 receptor accessory protein (IL1RAP); Dermcidin (DCD); Vitamin K-dependent protein Z (PROZ); Hepatocyte growth factor-like (HGFL); Cell surface glycoprotein (MUC18); 79 kDa glucose-regulated protein (GRP78); Coagulation factor V (FA5); Scavenger receptor cysteine-rich type 1 protein M130 (C163A); Neural cell adhesion molecule (NCAM1); Proteoglycan 4 (PRG4); Procollagen C-endopeptidase enhancer 1 (PCOC1); Plastin-2 OS Homo sapiens (PLSL); Coagulation factor XIII A chain (F13A); Fetuin-B (FETUB); Protein 5100-A6 (S10A); Metalloproteinase inhibitor 2 (TIMP2); Peroxiredoxin-1 (PRDX1); Macrophage colony-stimulating factor 1 receptor (CSF1R); Probable G protein coupled receptor 25 (GPR25); Putative zinc-alpha-2-glycoprotein-like 1 (ZAGL1); HLA class I histocompatibility antigen, B-15 alpha chain (1B15); Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA (MA1A1); Myelin P2 (MYP2); Metalloproteinase inhibitor 1 (TIMP1); HLA class I histocompatibility antigen, A-1 alpha chain (1A01); Haptoglobin-alpha isoform 2 (HPT2a); and Haptoglobin-alpha isoform 2 having a post-translational modification in the sequence CEADDGCPK (SEQ ID No. 32) comprising at least one of carbamidomethylation of C1, methylation of D4, methylation of D5, and acetylation of K9, in a biological fluid sample obtained from the subject, wherein the biological fluid is selected from peripheral whole blood, serum and plasma. An increased severity of COPD is indicated in the subject diagnosed with COPD if any of the following is determined: a) the presence of one or more of LMBL3, CAMP, CNTN1, VCAM1, IL1RAP, DCD and PROZ is detected; b) an increased level of one or more of HGFL, MUC18, GRP78, FA5, HPT2a and HPT2a-PTM is assessed, relative to the level of the biomarker in a biological fluid sample from a normal reference; c) a decreased level of one or more of C163A, NCAM1, PRG4, PCOC1, PLSL, F13A, and FETUB is assessed, relative to the level of the biomarker in a biological fluid sample from a normal reference; and/or d) a decreased level of one or more of S10A, TIMP2, PRDX1, CSF1R, GPR25, ZAGL1, 1B15, MA1A1, MYP2, TIMP1, and 1A01 is assessed, relative to the level of the biomarker in a biological fluid sample from a normal reference.

In an embodiment of the method for assessing severity of COPD, the biological fluid is plasma or serum.

In an embodiment of the method for assessing severity of COPD, the at least one biomarker is selected from HPT2a, GRP78, HGFL, and IL1RAP.

In an embodiment method for assessing severity of COPD, at least two or more biomarkers are detected or assessed. In an embodiment, at least one of the at least two biomarker is selected from HPT2a, GRP78, HGFL, and IL1RAP.

In an embodiment of the method for assessing severity of COPD, at least three or more biomarkers are detected or assessed. In an embodiment, the at least three or more biomarkers comprise HPT2a, GRP78, HGFL, and IL1RAP.

A method of monitoring susceptibility of developing COPD in a subject at risk of developing COPD is also provided. The method comprises i) detecting the presence of or assessing the level of a biomarker from the group comprising Lethal (3) malignant brain tumor-like 3 protein (LMBL3); Cathelicidin antimicrobial peptide (CAMP); Contactin-1 (CNTN1); Vascular cell adhesion protein 1 (VCAM1); Interleukin-1 receptor accessory protein (IL1RAP); Dermcidin (DCD); Vitamin K-dependent protein Z (PROZ); Hepatocyte growth factor-like (HGFL); Cell surface glycoprotein (MUC18); 79 kDa glucose-regulated protein (GRP78); Coagulation factor V (FA5); Scavenger receptor cysteine-rich type 1 protein M130 (C163A); Neural cell adhesion molecule (NCAM1); Proteoglycan 4 (PRG4); Procollagen C-endopeptidase enhancer 1 (PCOC1); Plastin-2 OS Homo sapiens (PLSL); Coagulation factor XIII A chain (F13A); Fetuin-B (FETUB); Protein S100-A6 (S10A); Metalloproteinase inhibitor 2 (TIMP2); Peroxiredoxin-1 (PRDX1); Macrophage colony-stimulating factor 1 receptor (CSF1R); Probable G protein coupled receptor 25 (GPR25); Putative zinc-alpha-2-glycoprotein-like 1 (ZAGL1); HLA class I histocompatibility antigen, B-15 alpha chain (1B15); Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA (MA1A1); Myelin P2 (MYP2); Metalloproteinase inhibitor 1 (TIMP1); HLA class I histocompatibility antigen, A-1 alpha chain (1A01); Haptoglobin-alpha isoform 2 (HPT2a); and Haptoglobin-alpha isoform 2 having a post-translational modification in the sequence CEADDGCPK (SEQ ID No. 32) comprising at least one of carbamidomethylation of C1, methylation of D4, methylation of D5, and acetylation of K9, in a first biological fluid sample from an at-risk subject diagnosed with COPD obtained at a first time point; ii) detecting the presence of or assessing the level of the biomarker in a second biological fluid sample from the at-risk subject obtained at a second time point; and iii) comparing the level of the biomarker detected or assessed in the first sample to the level of the biomarker detected or assessed in the second sample. An increase in susceptibility of developing COPD is indicated for the at-risk subject is any of the following is determined: a) the presence of one or more of LMBL3, CAMP, CNTN1, VCAM1, IL1RAP, DCD, and PROZ is detected in the second biological fluid sample; b) an increased level of one or more of HGFL, MUC18, GRP78, FA5, HPT2a and HPT2a-PTM is assessed in the second biological sample relative to the level in first biological fluid sample; c) a decreased level of one or more of C163A, NCAM1, PRG4, PCOC1, PLSL, F13A, and FETUB is assessed in the second biological sample relative to the level in first biological fluid sample; and/or d) a decreased level of one or more of S10A, TIMP2, PRDX1, CSF1R, GPR25, ZAGL1, 1B15, MA1A1, MYP2, TIMP1, and 1A01 is assessed in the second biological sample relative to the level in first biological fluid sample.

In an embodiment of the method of monitoring susceptibility of developing COPD, the biological fluid is plasma or serum.

In an embodiment of the method of monitoring susceptibility of developing COPD, the at least one biomarker is selected from HPT2a, GRP78, HGFL, and IL1RAP.

In an embodiment of the method of monitoring susceptibility of developing COPD, at least two or more biomarkers are detected or assessed. In an embodiment, at least one of the at least two biomarker is selected from HPT2a, GRP78, HGFL, and IL1RAP.

In an embodiment of the method of monitoring susceptibility of developing COPD, at least three or more biomarkers are detected or assessed. In an embodiment, the at least three or more biomarkers comprise HPT2a, GRP78, HGFL, and IL1RAP.

Further provided is a method of monitoring the progression of COPD in a subject diagnosed with COPD. The method comprises i) detecting the presence of or assessing the level of a biomarker from the group comprising Lethal (3) malignant brain tumor-like 3 protein (LMBL3); Cathelicidin antimicrobial peptide (CAMP); Contactin-1 (CNTN1); Vascular cell adhesion protein 1 (VCAM1); Interleukin-1 receptor accessory protein (IL1RAP); Dermcidin (DCD); Vitamin K-dependent protein Z (PROZ); Hepatocyte growth factor-like (HGFL); Cell surface glycoprotein (MUC18); 79 kDa glucose-regulated protein (GRP78); Coagulation factor V (FA5); Scavenger receptor cysteine-rich type 1 protein M130 (C163A); Neural cell adhesion molecule (NCAM1); Proteoglycan 4 (PRG4); Procollagen C-endopeptidase enhancer 1 (PCOC1); Plastin-2 OS Homo sapiens (PLSL); Coagulation factor XIII A chain (F13A); Fetuin-B (FETUB); Protein S100-A6 (S10A); Metalloproteinase inhibitor 2 (TIMP2); Peroxiredoxin-1 (PRDX1); Macrophage colony-stimulating factor 1 receptor (CSF1R); Probable G protein coupled receptor 25 (GPR25); Putative zinc-alpha-2-glycoprotein-like 1 (ZAGL1); HLA class I histocompatibility antigen, B-15 alpha chain (1B15); Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA (MA1A1); Myelin P2 (MYP2); Metalloproteinase inhibitor 1 (TIMP1); HLA class I histocompatibility antigen, A-1 alpha chain (1A01); Haptoglobin-alpha isoform 2 (HPT2a); and Haptoglobin-alpha isoform 2 having a post-translational modification in the sequence CEADDGCPK (SEQ ID No. 32) comprising at least one of carbamidomethylation of C1, methylation of D4, methylation of D5, and acetylation of K9, in a first biological fluid sample from a subject diagnosed with COPD obtained at a first time point; ii) detecting the presence of or assessing the level of the biomarker in a second biological fluid sample from the subject obtained at a second time point; and iii) comparing the level of the biomarker detected or assessed in the first sample to the level of the biomarker detected or assessed in the second sample. Progression of COPD in the subject is indicated if any of the following is determined: a) the presence of one or more of LMBL3, CAMP, CNTN1, VCAM1, IL1RAP, DCD, and PROZ is detected in the second biological fluid sample; b) an increased level of one or more of HGFL, MUC18, GRP78, FA5, HPT2a and HPT2a-PTM is assessed in the second biological sample relative to the level in first biological fluid sample; c) a decreased level of one or more of C163A, NCAM1, PRG4, PCOC1, PLSL, F13A, and FETUB is assessed in the second biological sample relative to the level in first biological fluid sample; and/or d) a decreased level of one or more of S10A, TIMP2, PRDX1, CSF1R, GPR25, ZAGL1, 1B15, MA1A1, MYP2, TIMP1, and 1A01 is assessed in the second biological sample relative to the level in first biological fluid sample.

In an embodiment of the method of monitoring the progression of COPD in a subject diagnosed with COPD, the biological fluid is plasma or serum.

In an embodiment of the method of monitoring the progression of COPD, the at least one biomarker is selected from HPT2a, GRP78, HGFL, and IL1RAP.

In an embodiment of the method of monitoring the progression of COPD, at least two or more biomarkers are detected or assessed. In an embodiment, at least one of the at least two biomarker is selected from HPT2a, GRP78, HGFL, and IL1RAP.

In an embodiment of the method of monitoring the progression of COPD, at least three or more biomarkers are detected or assessed. In an embodiment, the at least three or more biomarkers comprise HPT2a, GRP78, HGFL, and IL1RAP.

A method for assessing risk of COPD characterized by moderate or severe airway obstruction in a subject diagnosed with COPD is provided. The method comprises assessing the level of a biomarker from the group comprising Hepatocyte growth factor-like (HGFL); 79 kDa glucose-regulated protein (GRP78); and Scavenger receptor cysteine-rich type 1 protein M130 (C163A), in a biological fluid sample obtained from the subject, wherein the biological fluid is selected from peripheral whole blood, serum and plasma. If a) an increased level of one or more of HGFL and GRP78 is assessed, relative to the level of the biomarker in a biological fluid sample from a normal reference; and/or b) a decreased level of C163A is assessed, relative to the level of the biomarker in a biological fluid sample from a normal reference, then increased risk of COPD characterized by moderate or severe airway obstruction is indicated in the subject diagnosed with COPD. In an embodiment, the biological fluid is plasma or serum.

In an embodiment, the greater the increased level of HGFL, the increased level of GRP78, and/or the decreased level of C163A, the greater the risk of COPD characterized by moderate or severe obstruction in the subject diagnosed with COPD.

In an embodiment, the level of GRP78 and the level of HGFL are assessed.

Further provided is a method of monitoring the progression of airway obstruction in a subject diagnosed with COPD. The method comprises i) assessing the level of a biomarker from the group comprising Hepatocyte growth factor-like (HGFL); 79 kDa glucose-regulated protein (GRP78); and Scavenger receptor cysteine-rich type 1 protein M130 (C163A) in a first biological fluid sample from a subject diagnosed with COPD obtained at a first time point, wherein the biological fluid is selected from peripheral whole blood, serum and plasma; ii) assessing the level of the biomarker in a second biological fluid sample from the subject obtained at a second time point; and iii) comparing the level of the biomarker assessed in the first sample to the level of the biomarker detected or assessed in the second sample. If a) an increased level of one or more of HGFL and GRP78 is assessed in the second biological sample relative to the level in first biological fluid sample; and/or b) a decreased level of C163A is assessed in the second biological sample relative to the level in first biological fluid sample, then progression of airway obstruction in the subject is indicated. In an embodiment, the biological fluid is plasma or serum.

In an embodiment, the greater the increased level of HGFL, the increased level of GRP78, and/or the decreased level of C163A, the greater the progression of airway obstruction in the subject diagnosed with COPD.

In an embodiment, the level of GRP78 and the level of HGFL are assessed.

BRIEF DESCRIPTION OF THE DRAWINGS

For the purpose of illustrating the methods disclosed herein, there are depicted in the drawings certain embodiments. However, the methods and related products are not limited to the precise arrangements and instrumentalities of the embodiments depicted in the drawings.

FIGS. 1A and 1B are tables summarizing the phenotypic characteristics of the subjects whose plasma was studied. BMI=body mass index. M=male. C=Caucasian. FEV₁=the volume of air forcefully expired during the first second after taking a full breath. FVC=forced vital capacity; the total volume of air expired with maximal force.

FIG. 2 depicts representative images of Western blots of plasma from ex-smokers without COPD (“GOLD 0”; left) and subjects diagnosed with very severe COPD (“GOLD IV”; right), probed with an anti-GRP78 antibody. Blots were quantitated using densitometry and normalized to IgG light chain. The quantitative data are plotted below the Western blot images as box plots, wherein the box represents the interquartile range.

FIG. 3 depicts representative images of Western blots of plasma from GOLD 0 (left) and GOLD IV (right) subjects probed with an anti-IL1RAP antibody. Blots were quantitated using densitometry and normalized to IgG light chain. The quantitative data are plotted below the Western blot images as box plots, wherein the box represents the interquartile range.

FIG. 4 depicts representative images of Western blots of plasma from GOLD 0 (left) and GOLD IV (right) subjects probed with an anti-HGFL antibody. Blots were quantitated using densitometry and normalized to IgG light chain. The quantitative data are plotted below the Western blot images as box plots, wherein the box represents the interquartile range.

FIG. 5 depicts images of 2-DE gels of pooled protein extracts from GOLD O (left panel) and GOLD IV (right panel) subjects. The arrows point to three haptoglobin-alpha isoforms, one of which was found to be up-regulated in GOLD IV as compared to GOLD 0.

FIGS. 6A and 6B are a series of images of 2-DE gels and a boxplot of the data. FIG. 6A is a series of zoom view images of 2-DE gels for 10 individual samples from GOLD 0 (left panels) and GOLD IV (right panels). The arrow points to haptoglobin-alpha. FIG. 6B is a boxplot of the GOLD 0 and GOLD IV data for haptoglobin-alpha isoform 2, wherein the box represents the interquartile range.

FIGS. 7A, 7B and 7C depict a series of receiver operating characteristic (“ROC”) curves. ROC curves are shown for four individual biomarkers, and combinations of these biomarkers. The biomarkers are: HPT2a (labeled HP in the figure) GRP78, IL1RAP, and HGFL (labeled HGFLa in the figure). AUC=area under curve.

FIGS. 8A-8D depict a series of graphs illustrating % predicted FEV₁ as a function of plasma concentration for four individual biomarkers. The biomarkers are: GRP78 (FIG. 8A), C163A (labeled sCD163; FIG. 8B), IL1RAP (labeled IL1AP; FIG. 8C), and HGFL (FIG. 8D). Plasma concentration for GRP78, IL1RAP and HGFL was determined by Western blot; band density of scans was normalized to IgG band density. Plasma concentration for C163A was determined by ELISA.

DEFINITIONS

As used herein, each of the following terms has the meaning associated with it in this section.

The articles “a” and “an” are used herein to refer to one or to more than one (i.e. to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.

The term “about” will be understood by persons of ordinary skill in the art and will vary to some extent depending on the context in which it is used. As used herein, “about” is meant to encompass variations of ±20%, more preferably ±10%, more preferably ±5%, even more preferably ±1%, and still more preferably ±0.1%.

As used herein, chronic obstructive pulmonary disease (COPD) refers to a chronic progressive lung disease. Chronic bronchitis and emphysema are non-limiting examples of COPD. COPD can be diagnosed by pulmonary function tests and/or chest X-rays in accordance with accepted clinical practice. Clinically relevant diagnostic tests include: FEV₁ (the volume of air forcefully expired during the first second after taking a full breath); forced vital capacity (FVC; the total volume of air expired with maximal force); and flow-volume loops, which are simultaneous spirometric recordings of airflow and volume during forced maximal expiration and inspiration. Reductions of FEV₁, FVC, and the ratio of FEV₁/FVC are hallmarks of airflow limitation. See Merck Manual Online for Healthcare Professionals, Pulmonary Disorders, Chronic Obstructive Pulmonary Disorder, Introduction (downloaded from www(dot)merckmanuals(dot)com/professional/sec05/ch049/ch049a(dot)html on 19 Dec. 2010). Severity of disease can be assessed on the same criteria.

GOLD is the abbreviation for the Global Initiative for Chronic Obstructive Lung Disease. GOLD classifications designate the severity of disease for COPD patients as shown in Table 1.

TABLE 1 GOLD classification Description Criteria 0 At-risk of COPD I Mild COPD FEV₁/FVC < 0.7 FEV₁ ≧ 80% predicted II Moderate COPD FEV₁/FVC < 0.7 50% ≦ FEV₁ < 80% predicted III Severe COPD FEV₁/FVC < 0.7 30% ≦ FEV1 < 50% predicted IV Very severe COPD FEV₁/FVC < 0.7 FEV1 < 30% predicted or FEV1 < 50% predicted with chronic respiratory failure

As used herein, “severity of COPD” refers generally to the extent of airflow limitation and optionally to associated symptoms such as chronic coughing and sputum production, as clinically defined parameters. The GOLD classifications are exemplary for classifying COPD severity.

“Increased severity of COPD” is used herein to refer to an increase in airflow limitation (e.g., increased limitation in airflow) and optionally to worsening of associated symptoms such as chronic coughing and sputum production in a COPD patient relative to a normal reference, or relative to the subject at an earlier point in time. An exemplary normal reference can be a non-smoker or an ex-smoker who does not have clinical evidence of COPD, or a population of non-smokers and/or ex-smokers who do not have clinical evidence of COPD. The normal reference can be representative of the patient with regard to approximate age, age group, body-mass index (“BMI”), gender and/or other parameters.

“At risk for developing COPD” refers to a subject having one or more risk factors for COPD. Risk factors known in the art include, but are not limited to, a history of tobacco smoking; long term exposure to one or more of organic dust, inorganic dust, chemical fumes, smoke such as from burning biomass or coal, gases, vapors and mists; and α₁-antitrypsin deficiency.

As used herein, the term “subject” or “patient” refers to any animal (e.g., a mammal) including, but not limited to, humans and non-human primates, at risk for developing COPD or diagnosed with COPD. Typically, the terms “subject” and “patient” are used interchangeably herein in reference to a human subject.

As used herein, a “normal subject” or “control subject” refers to a subject that does not manifest clinical symptoms of COPD.

As used herein, a “normal reference” refers to a normal subject or to a population of normal subjects.

“Increased susceptibility of developing COPD” is used herein to refer to an increase in the likelihood or possibility of a subject developing COPD relative to a normal reference, or relative to the subject at an earlier point in time. An exemplary normal reference can be a non-smoker or an ex-smoker who does not have clinical evidence of COPD, or a population of non-smokers and/or ex-smokers who do not have clinical evidence of COPD. The normal reference can be representative of the patient with regard to approximate age, age group, BMI, gender and/or other parameters.

“Delaying development of COPD” as used herein refers to a prolonging of the time to the development of COPD and/or delay in the progression of COPD, i.e., delaying an increase in COPD severity.

“Alleviating COPD,” as used herein, refers to a decrease in the severity of COPD, i.e., an increase in lung function, as assessed by conventional clinical methods including, but not limited to spirometry.

As used herein, a “detector molecule” is a molecule that may be used to detect a compound of interest. Non-limiting examples of a detector molecule are molecules that bind specifically to a compound of interest, such as, but not limited to, an antibody, a cognate receptor or binding partner, an aptamer, and a small molecule.

By the term “specifically binds,” as used herein with respect to a detector molecule such as an antibody, is meant a detector molecule that recognizes a specific binding partner, such as an antigen, but does not substantially recognize or bind other molecules in a sample. For instance, in a sample containing 79 kDa glucose-regulated protein (GRP78), an antibody that specifically binds to GRP78 does not substantially recognize or bind to other molecules in the sample.

The term “antibody,” as used herein, refers to an immunoglobulin molecule which is able to specifically bind to a specific epitope on an antigen. Antibodies can be intact immunoglobulins derived from natural sources or from recombinant sources and can be immunoreactive portions of intact immunoglobulins. The antibodies in the present invention may exist in a variety of forms including, for example, polyclonal antibodies, monoclonal antibodies, intracellular antibodies (“intrabodies”), Fv, Fab and F(ab)₂, as well as single chain antibodies (scFv), heavy chain antibodies, such as camelid antibodies, and humanized antibodies (Harlow et al., 1999, Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, NY; Harlow et al., 1989, Antibodies: A Laboratory Manual, Cold Spring Harbor, N.Y.; Houston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; Bird et al., 1988, Science 242:423-426).

By the term “synthetic antibody,” as used herein, is meant an antibody which is generated using recombinant DNA technology, such as, for example, an antibody expressed by a bacteriophage as described herein. The term should also be construed to mean an antibody which has been generated by the synthesis of a DNA molecule encoding the antibody and which DNA molecule expresses an antibody protein, or an amino acid sequence specifying the antibody, wherein the DNA or amino acid sequence has been obtained using synthetic DNA or amino acid sequence technology which is available and well known in the art.

As used herein, the term “heavy chain antibody” or “heavy chain antibodies” comprises immunoglobulin molecules derived from camelid species, either by immunization with a peptide and subsequent isolation of sera, or by the cloning and expression of nucleic acid sequences encoding such antibodies. The term “heavy chain antibody” or “heavy chain antibodies” further encompasses immunoglobulin molecules isolated from an animal with heavy chain disease, or prepared by the cloning and expression of V_(H) (variable heavy chain immunoglobulin) genes from an animal.

As used herein, an “immunoassay” refers to any binding assay that uses an antibody capable of binding specifically to a target molecule to detect and quantify the target molecule.

It is understood that any and all whole or partial integers between any ranges set forth herein are included herein.

DETAILED DESCRIPTION

The methods described herein are based on the discovery that the plasma level of a panel of specific proteins differs between two subject populations: 1) subjects at risk for chronic obstructive pulmonary disease (“COPD”) but not manifesting clinical symptoms of COPD; and 2) subjects having very severe COPD. The difference in plasma level is statistically significant for each protein. Each protein can therefore be used as a biomarker in: assessing risk of developing COPD in an at-risk subject; monitoring risk of developing COPD over time in an at-risk subject; assessing severity of disease in a subject diagnosed with COPD (“COPD patient”); monitoring disease progression over time in a COPD patient; and/or monitoring therapeutic efficacy over time in a COPD patient. Each protein may also be a candidate for developing therapeutics designed to modulate plasma level of the protein to approach the level observed for subjects not manifesting clinical symptoms of COPD.

The biomarkers useful in the practice of the methods described herein are proteins selected from the group comprising: Lethal (3) malignant brain tumor-like 3 protein (LMBL3); Cathelicidin antimicrobial peptide (CAMP); Contactin-1 (CNTN1); Vascular cell adhesion protein 1 (VCAM1); Interleukin-1 receptor accessory protein (IL1RAP); Dermcidin (DCD); Vitamin K-dependent protein Z (PROZ); Hepatocyte growth factor-like (HGFL); Cell surface glycoprotein (MUC18); 79 kDa glucose-regulated protein (GRP78); Coagulation factor V (FA5); Scavenger receptor cysteine-rich type 1 protein M130 (C163A); Neural cell adhesion molecule (NCAM1); Proteoglycan 4 (PRG4); Procollagen C-endopeptidase enhancer 1 (PCOC1); Plastin-2 OS Homo sapiens (PLSL); Coagulation factor XIII A chain (F13A); Fetuin-B (FETUB); Protein S100-A6 (S10A); Metalloproteinase inhibitor 2 (TIMP2); Peroxiredoxin-1 (PRDX1); Macrophage colony-stimulating factor 1 receptor (CSF1R); Probable G protein coupled receptor 25 (GPR25); Putative zinc-alpha-2-glycoprotein-like 1 (ZAGL1); HLA class I histocompatibility antigen, B-15 alpha chain (1B15); Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA (MA1A1); Myelin P2 (MYP2); Metalloproteinase inhibitor 1 (TIMP1); HLA class I histocompatibility antigen, A-1 alpha chain (1A01); Haptoglobin-alpha isoform 2 (HPT2a); and HPT2a comprising one or more of four specific post-translational modifications described elsewhere herein (HPT2a-PTM). These proteins can be divided into four categories of expression level: 1) proteins that are present only in subjects having very severe COPD; 2) proteins that are present at a higher level (“up-regulated”) in subjects having very severe COPD; 3) proteins that are present at a lower level (“down-regulated”) in subjects having very severe COPD; and 4) proteins present only in at-risk subjects not manifesting clinical symptoms of COPD.

The biomarkers were identified in blood plasma prepared from a peripheral blood sample. It is contemplated that the biomarkers will similarly be present in any peripheral blood-derived sample, such as whole blood and blood serum. Therefore, the methods of the invention may be practiced with a biological fluid sample selected from whole blood, plasma and blood serum. The preferred biological fluid sample is plasma.

The proteins discovered to be present in plasma of subjects having very severe COPD but not present in plasma in subjects not manifesting clinical symptoms of COPD are shown in Table 2.

TABLE 2 SwissProt Protein Accession Seq ID Protein Name ID No. No. Lethal (3) malignant brain LMBL3 Q96JM7 1 tumor-like 3 protein Cathelicidin antimicrobial peptide CAMP P49913 2 Contactin-1 CNTN1 Q12860 3 Vascular cell adhesion protein 1 VCAM1 P19320 4 Interleukin-1 receptor accessory IL1RAP Q9NPH3 5 protein Dermcidin DCD P81605 6 Vitamin K-dependent protein Z PROZ P22891 7

If any one or more of LMBL3, CAMP, CNTN1, VCAM1, IL1RAP, DCD, and PROZ is detected in a biological fluid sample from a subject at risk for COPD, the subject is at an elevated susceptibility for developing COPD. If any one or more of LMBL3, CAMP, CNTN1, VCAM1, IL1RAP, DCD, and PROZ is detected in a biological fluid sample from a subject diagnosed with COPD, the subject is likely to have an increased severity of COPD. An increase in expression level in a biological fluid sample of any one or more of LMBL3, CAMP, CNTN1, VCAM1, IL1RAP, DCD, and PROZ over time in a subject with COPD correlates with disease progression. Similarly, decreased expression of any one or more of LMBL3, CAMP, CNTN1, VCAM1, IL1RAP, DCD, and PROZ in a biological fluid sample of a subject with COPD undergoing therapy correlates with an increase in efficacy of the treatment, thereby enabling monitoring of therapeutic efficacy. Expression of these seven biomarkers is not detectable in normal subjects, therefore, decreased expression encompasses a non-detectable level of expression.

The proteins discovered to be present at a higher level (“up-regulated”) in plasma of subjects having very severe COPD proteins compared to the level in plasma of subjects not manifesting clinical symptoms of COPD are shown in Table 3.

TABLE 3 SwissProt Protein Accession Seq ID Protein Name ID No. No. Hepatocyte growth factor-like HGFL P26927 8 Cell surface glycoprotein MUC18 P43121 9 79 kDa glucose-regulated protein GRP78 P11021 10 Coagulation factor V FA5 P12259 11 Haptoglobin-alpha isoform 2 HPT2a† P00738 12 †This is the protein ID used herein to refer to residues 19-160 of the amino acid sequence of SwissProt Accession No. P00738 (Protein ID HPT2; SEQ ID No. 31).

If any one or more of HGFL, MUC18, GRP78, FA5, and HPT2a is detected at an elevated level in a biological fluid sample from a subject at risk for COPD relative to the level in a normal reference, the subject is at an elevated susceptibility for developing COPD. If any one or more of HGFL, MUC18, GRP78, FA5, and HPT2a is detected at an elevated level in a biological fluid sample from a COPD patient relative to a normal reference, the patient is likely to have an increased severity of COPD. In addition, an increase in expression level in a biological fluid sample of any one or more of HGFL, MUC18, GRP78, FA5, and HPT2a over time in a COPD patient correlates with disease progression. Similarly, decreased expression of any one or more of HGFL, MUC18, GRP78, FA5, and HPT2a in a biological fluid sample of a COPD patient undergoing therapy correlates with an increase in efficacy of the treatment, thereby enabling monitoring of therapeutic efficacy.

It has further been discovered that HPT2a comprises four post-translational modifications (PTMs) in very severe COPD patients that are not present in subjects at risk for COPD. The modifications comprise: carbamidomethylation of the first cysteine, methylation of the two aspartic acids, and acetylation of the lysine in the sequence CEADDGCPK (SEQ ID No. 32). These modified residues correspond to corresponds to carbamidomethylation of cysteine 68, methylation of aspartic acid 71, methylation of aspartic acid 72, and acetylation of lysine 76 of SEQ ID No. 12. As used herein, “HPT2a-PTM” refers to HPT2a comprising one or more of these post-translational modifications. The detection of HPT2a-PTM in a subject at risk for COPD is indicative of the subject having an elevated susceptibility of developing COPD. If HPT2a-PTM is detected in a biological fluid sample from a COPD patient relative to a normal reference, the patient is likely to have an increased severity of COPD. Detecting an increase in HPT2a-PTM over time in a COPD patient is expected to correlate with disease progression. Likewise, detecting a decrease in HPT2a-PTM in a biological fluid sample of a COPD patient undergoing therapy is expected to correlate with an increase in efficacy of the treatment, thereby enabling monitoring of therapeutic efficacy.

The proteins discovered to be present at a decreased level (“down-regulated”) in plasma of subjects having very severe COPD compared to the level in plasma of subjects not manifesting clinical symptoms of COPD are shown in Table 4.

TABLE 4 SwissProt Protein Accession Seq ID Protein Name ID No. No. Scavenger receptor cysteine-rich C163A Q86VB7 13 type 1 protein M130 Neural cell adhesion molecule NCAM1 P13591 14 Proteoglycan 4 PRG4 Q92954 15 Procollagen C-endopeptidase PCOC1 Q15133 16 enhancer 1 Plastin-2 OS Homo sapiens PLSL P13796 17 Coagulation factor XIII A chain F13A P00488 18 Fetuin-B FETUB Q9UGM5 19

If any one or more of C163A, NCAM1, PRG4, PCOC1, PLSL, F13A, and FETUB is detected at a decreased level in a biological fluid sample from a subject at risk for COPD relative to the level in a normal reference, the subject is at an elevated susceptibility for developing COPD. If any one or more of C163A, NCAM1, PRG4, PCOC1, PLSL, F13A, and FETUB is detected at a decreased level in a biological fluid sample from a COPD patient relative to a normal reference, the patient is likely to have COPD of increased severity. A decrease in expression level in a biological fluid sample of any one or more of C163A, NCAM1, PRG4, PCOC1, PLSL, F13A, and FETUB over time in a COPD patient correlates with disease progression. Similarly, increased level of any one or more of C163A, NCAM1, PRG4, PCOC1, PLSL, F13A, and FETUB in a biological fluid sample of a COPD patient undergoing therapy correlates with an increase in efficacy of the treatment, thereby enabling monitoring of therapeutic efficacy.

The proteins discovered to be present only in plasma of at-risk subjects not manifesting clinical symptoms of COPD but not present in plasma in subjects having very severe COPD are shown in Table 5.

TABLE 5 SwissProt Protein Accession Seq ID Protein Name ID No. No. Protein S100-A6 S10A P06703 20 Metalloproteinase inhibitor 2 TIMP2 P16035 21 Peroxiredoxin-1 PRDX1 Q06830 22 Macrophage colony-stimulating factor 1 CSF1R P07333 23 receptor Probable G protein coupled receptor 25 GPR25 O00155 24 Putative zinc-alpha-2-glycoprotein- ZAGL1 A8MT79 25 like 1 HLA class I histocompatibility antigen, 1B15 P30464 26 B-15 alpha chain Mannosyl-oligosaccharide 1,2-alpha- MA1A1 P33908 27 mannosidase IA Myelin P2 MYP2 P02689 28 Metalloproteinase inhibitor 1 TIMP1 P01033 29 HLA class I histocompatibility antigen, 1A01 P30443 30 A-1 alpha chain

If any one or more of S10A, TIMP2, PRDX1, CSF1R, GPR25, ZAGL1, 1B15, MA1A1, MYP2, TIMP1, and 1A01 is detected at a decreased level in a biological fluid sample from a subject at risk for COPD relative to the level in a normal reference, the subject is at an elevated susceptibility for developing COPD. If any one or more of S10A, TIMP2, PRDX1, CSF1R, GPR25, ZAGL1, 1B15, MA1A1, MYP2, TIMP1, and 1A01 is detected at a decreased level in a biological fluid sample from a COPD patient relative to a normal reference, the patient is likely to have COPD of increased severity. A decrease in expression level in a biological fluid sample of any one or more of S10A, TIMP2, PRDX1, CSF1R, GPR25, ZAGL1, 1B15, MA1A1, MYP2, TIMP1, and 1A01 over time in a COPD patient correlates with disease progression. Similarly, increased level of any one or more of S10A, TIMP2, PRDX1, CSF1R, GPR25, ZAGL1, 1B15, MA1A1, MYP2, TIMP1, and 1A01 in a biological fluid sample of a COPD patient undergoing therapy correlates with an increase in efficacy of the treatment, thereby enabling monitoring of therapeutic efficacy. For this group of biomarkers, decreased levels includes no detectable presence at all of a biomarker in the biological sample, since no detectable presence of these biomarkers was found in COPD patients having very severe COPD.

Exemplary amino acid sequences for the biomarkers are provided in SEQ ID Nos. 1-30. See also Table 11. It is well-known in the art that proteins can exist in a biological sample in a plurality of different forms. These forms can result from either or both of pre- and post-translational modifications. Pre-translationally modified forms include allelic variants, splice variants and RNA editing forms. Post-translationally modified forms include forms resulting from proteolytic cleavage (e.g., cleavage of a signal sequence or fragments of a parent protein), glycosylation, phosphorylation, lipidation, oxidation, methylation, cysteinylation, sulphonation and acetylation.

Thus, in addition to the specific biomarker sequences identified herein by name or accession number, the invention also contemplates the detection in a test sample of naturally-occurring variants that are at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the exemplified biomarker sequences in SEQ ID Nos. 1-30. Detection of such naturally-occurring variants in a biological fluid sample of a subject may be used in the methods described and claimed.

The determination of percent identity between two nucleotide or amino acid sequences can be accomplished using a mathematical algorithm. For example, a mathematical algorithm useful for comparing two sequences is the algorithm of Karlin and Altschul (1990, Proc. Natl. Acad. Sci. USA 87:2264-2268), modified as in Karlin and Altschul (1993, Proc. Natl. Acad. Sci. USA 90:5873-5877). This algorithm is incorporated into the NBLAST and XBLAST programs of Altschul, et al. (1990, J. Mol. Biol. 215:403-410), and can be accessed, for example at the National Center for Biotechnology Information (NCBI) world wide web site having the universal resource locator “http://blast(dot)ncbi(dot)nlm(dot)nih(dot)gov/Blast(dot)cgi”. BLAST nucleotide searches can be performed with the NBLAST program (designated “blastn” at the NCBI web site), using the following parameters: gap penalty=5; gap extension penalty=2; mismatch penalty=3; match reward=1; expectation value 10.0; and word size=11 to obtain nucleotide sequences homologous to a nucleic acid described herein. BLAST protein searches can be performed with the XBLAST program (designated “blastn” at the NCBI web site) or the NCBI “blastp” program, using the following parameters: expectation value 10.0, BLOSUM62 scoring matrix to obtain amino acid sequences homologous to a protein molecule described herein. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (1997, Nucleic Acids Res. 25:3389-3402). Alternatively, PSI-Blast or PHI-Blast can be used to perform an iterated search which detects distant relationships between molecules (Id.) and relationships between molecules which share a common pattern. When utilizing BLAST, Gapped BLAST, PSI-Blast, and PHI-Blast programs, the default parameters of the respective programs (e.g., XBLAST and NBLAT) can be used.

With regard to HPT2a-PTm, the invention encompasses detection of a post-translational modification at at least one of residues C68, D71, D72 and K76 of SEQ ID No. 12. The post-translation modification for C68 is carbamidomethylation. The post-translation modification for D71 and D72 is methylation; and the post-translational modification for K76 is acetylation. Detection of such modifications can be done by any method known in the art including, but not limited to, mass spectroscopy and immunoassay.

Assessment of Susceptibility of Developing COPD

The invention provides a method of assessing susceptibility of developing COPD in a subject at risk of COPD. The method comprises detecting the presence of or assessing the level of a biomarker in a biological fluid sample obtained from the subject, wherein if: a) the presence of one or more of LMBL3, CAMP, CNTN1, VCAM1, IL1RAP, DCD, and PROZ is detected; b) an increased level of one or more of HGFL, MUC18, GRP78, FA5, HPT2a and HPT2a-PTM is assessed, relative to the level of the same biomarker in the same type of biological fluid sample in a normal reference; c) a decreased level of one or more of C163A, NCAM1, PRG4, PCOC1, PLSL, F13A, and FETUB is assessed, relative to the level of the same biomarker in the same type of biological fluid sample in a normal reference; and/or d) a decreased level of one or more of S10A, TIMP2, PRDX1, CSF1R, GPR25, ZAGL1, 1B15, MA1A1, MYP2, TIMP1, and 1A01 is assessed, relative to the level of the same biomarker in the same type of biological fluid sample in a normal reference; then an increased susceptibility of developing COPD is indicated in the at-risk subject.

In some embodiments of the invention, COPD susceptibility assessment can be determined by comparison of the level of a marker for an at-risk subject to a normal reference, wherein the normal reference is a reference database of levels for that biomarker in normal patients. The reference database can be generated by measuring the same marker under the same conditions in a representative population. Typically the representative population is a population of patients who do not have clinical evidence of COPD. The reference database can be divided into quartiles, wherein the interquartile range is defined by the 25^(th) and 75^(th) percentile, and has a median. For LMBL3, CAMP, CNTN1, VCAM1, IL1RAP, DCD, PROZ, HGFL, MUC18, GRP78, FA5, HPT2a and HPT2a-PTM, if the test level for the at-risk subject exceeds the interquartile range for the reference database and/or exceeds the median value for the reference database, the conclusion is that the patient has an increased susceptibility for developing COPD. Similarly, for C163A, NCAM1, PRG4, PCOC1, PLSL, F13A, FETUB, S10A, TIMP2, PRDX1, CSF1R, GPR25, ZAGL1, 1B15, MA1A1, MYP2, TIMP1, and 1A01, if the test level for the at-risk subject is less than the interquartile range for the reference database and/or less than the median value for the reference database, the conclusion is that the at-risk subject has an increased susceptibility for developing COPD.

The invention also provides a method of assessing susceptibility of developing COPD in an at-risk subject as a function of time. The method comprises assessing the level of a biomarker in a biological fluid sample at a first point in time to establish a baseline level of the biomarker. The method further comprises assessing the level of the same biomarker at a second point in time in order to identify whether the level of the marker is changing. For a biomarker selected from the group comprising C163A, NCAM1, PRG4, PCOC1, PLSL, F13A, FETUB, S10A, TIMP2, PRDX1, CSF1R, GPR25, ZAGL1, 1B15, MA1A1, MYP2, TIMP1, and 1A01, if the second level is less than the baseline level, it is indicative of an increased susceptibility of developing COPD. For a biomarker selected from the group comprising LMBL3, CAMP, CNTN1, VCAM1, IL1RAP, DCD, PROZ, HGFL, MUC18, GRP78, FA5, HPT2a and HPT2a-PTM, if the second level is greater than the baseline level, it is indicative of an increased susceptibility of developing COPD. The second assessing step is generally performed at least one day after the baseline assessment. It can also be performed multiple days, weeks, months or years after the baseline assessment. Moreover, the second assessing step can be performed iteratively over time to acquire additional data and thereby monitor the risk over an extended period of time. Rate of change in expression levels can be calculated to identify if there is an increasing trend to reduced expression for a biomarker selected from the group comprising C163A, NCAM1, PRG4, PCOC1, PLSL, F13A, FETUB, S10A, TIMP2, PRDX1, CSF1R, GPR25, ZAGL1, 1B15, MA1A1, MYP2, TIMP1, and 1A01, or a increasing trend to increased expression for a biomarker selected from the group comprising LMBL3, CAMP, CNTN1, VCAM1, IL1RAP, DCD, PROZ, HGFL, MUC18, GRP78, FA5, HPT2a and HPT2a-PTM, which would be indicative of an increasing susceptibility to develop COPD.

Assessment of Severity of COPD

The invention also provides a method for assessing severity of COPD in a subject diagnosed with COPD. The method comprises detecting the presence of or assessing the level of a biomarker in a biological fluid sample obtained from the COPD patient, wherein if: a) the presence of one or more of LMBL3, CAMP, CNTN1, VCAM1, IL1RAP, DCD, and PROZ is detected; b) an increased level of one or more of HGFL, MUC18, GRP78, FA5, HPT2a and HPT2a-PTM is assessed, relative to the level of the biomarker in a normal reference; c) a decreased level of one or more of C163A, NCAM1, PRG4, PCOC1, PLSL, F13A, and FETUB is assessed, relative to the level of the biomarker in a normal reference; and/or d) a decreased level of one or more of S10A, TIMP2, PRDX1, CSF1R, GPR25, ZAGL1, 1B15, MA1A1, MYP2, TIMP1, and 1A01 is assessed, relative to the level of the biomarker in a normal reference, then increased severity of COPD is indicated in the COPD patient.

In some embodiments of the invention, severity assessment can be determined by comparison of the level of a biomarker for COPD patient to a normal reference, wherein the normal reference is a reference database of levels for that biomarker in normal subjects. The reference database can be generated as discussed above. Specifically, the reference database can be generated by measuring the same biomarker under the same conditions in a representative population. In an embodiment, the representative population is a population of patients who do not have clinical evidence of COPD. The reference database can be divided into quartiles, wherein the interquartile range is defined by the 25^(th) and 75^(th) percentile, and has a median. For LMBL3, CAMP, CNTN1, VCAM1, IL1RAP, DCD, PROZ, HGFL, MUC18, GRP78, FA5, HPT2a and HPT2a-PTM, if the test level for the COPD patient exceeds the interquartile range for the reference database and/or exceeds the median value for the reference database, the conclusion is that the patient has an increased severity of COPD. Similarly, for C163A, NCAM1, PRG4, PCOC1, PLSL, F13A, FETUB, S10A, TIMP2, PRDX1, CSF1R, GPR25, ZAGL1, 1B15, MA1A1, MYP2, TIMP1, and 1A01, if the test level for the COPD patient is less than the interquartile range for the reference database for the reference database and/or less than the median value for the reference database, the conclusion is that the patient has an increased severity of COPD.

In another embodiment, assessing severity of COPD in a subject diagnosed with COPD can be determined by comparison of the level of a biomarker for the COPD patient to a reference database of levels for that biomarker in COPD patients, stratified for different clinical degrees of severity of disease.

The invention also provides a method of assessing COPD disease progression in a COPD patient as a function of time. The method comprises assessing the level of a biomarker in a biological fluid sample from the COPD patient at a first point in time to establish a baseline level of the biomarker. The method further comprises assessing the level of the same biomarker in a second biological fluid sample obtained at a second point in time in order to identify whether the level of the biomarker is changing. For a biomarker selected from the group comprising C163A, NCAM1, PRG4, PCOC1, PLSL, F13A, FETUB, S10A, TIMP2, PRDX1, CSF1R, GPR25, ZAGL1, 1B15, MA1A1, MYP2, TIMP1, and 1A01, if the second level is less than the baseline level, it is indicative of disease progression. For a biomarker selected from S10A, TIMP2, PRDX1, CSF1R, GPR25, ZAGL1, 1B15, MA1A1, MYP2, TIMP1, and 1A01, loss of detectable expression can be indicative of very severe COPD. For a biomarker selected from the group comprising LMBL3, CAMP, CNTN1, VCAM1, IL1RAP, DCD, PROZ, HGFL, MUC18, GRP78, FA5, HPT2a and HPT2a-PTM, if the second level is greater than the baseline level, it is indicative of disease progression. The second assessing step is generally performed at least one day after the baseline assessment. It can also be performed multiple days, weeks, months or years after the baseline assessment. Moreover, the second assessing step can be performed iteratively over time to acquire additional data and thereby monitor the disease progression over an extended period of time. Rate of change in expression levels can be calculated to identify if there is an increasing trend to reduced expression for a biomarker selected from the group comprising C163A, NCAM1, PRG4, PCOC1, PLSL, F13A, FETUB, S10A, TIMP2, PRDX1, CSF1R, GPR25, ZAGL1, 1B15, MA1A1, MYP2, TIMP1, and 1A01, or a increasing trend to increased expression for a biomarker selected from the group comprising LMBL3, CAMP, CNTN1, VCAM1, IL1RAP, DCD, PROZ, HGFL, MUC18, GRP78, FA5, HPT2a and HPT2a-PTM, which would be indicative of disease progression.

Assessment of disease progression over time can also be performed while the patient is undergoing treatment with one or more pharmaceutical agents to monitor the likelihood that the treatment is delaying development of COPD or alleviating COPD. As used herein, “pharmaceutical agent” encompasses a single agent or a plurality of agents.

In the method of assessing disease progression over time, a baseline level of the biomarker in a biological fluid is assessed while treatment with the one or more pharmaceutical agents is not occurring, such as prior to treatment initiation. After the initiation of treatment, the level of the biomarker (“treatment level”) is assessed at at least one later time point. If the treatment level is the same or greater than the baseline level for a biomarker selected from the group comprising C163A, NCAM1, PRG4, PCOC1, PLSL, F13A, FETUB, S10A, TIMP2, PRDX1, CSF1R, GPR25, ZAGL1, 1B15, MA1A1, MYP2, TIMP1, and 1A01, the likelihood increases that development of COPD is delayed by the pharmaceutical agent and/or the pharmaceutical agent is alleviating COPD. For LMBL3, CAMP, CNTN1, VCAM1, IL1RAP, DCD, PROZ, HGFL, MUC18, GRP78, FA5, HPT2a or HPT2a-PTM as the biomarker, if the treatment level is the same or less than the baseline level, the likelihood increases that development of COPD is delayed by the treatment with the pharmaceutical agent and/or the treatment with the pharmaceutical agent is alleviating COPD. The biomarker treatment level can alternatively or additionally be compared to a database of biomarker level measurements in a population not being treated with the pharmaceutical agent to assess whether COPD development is delayed and/or COPD is alleviated. If the biomarker treatment level is greater than an average measurement or range of measurements of the treatment level in the untreated population for a biomarker selected from the group comprising C163A, NCAM1, PRG4, PCOC1, PLSL, F13A, FETUB, S10A, TIMP2, PRDX1, CSF1R, GPR25, ZAGL1, 1B15, MA1A1, MYP2, TIMP1, and 1A01, that is also indicative that of an increased likelihood that COPD development is delayed by the pharmaceutical agent and/or the pharmaceutical agent is alleviating COPD. For LMBL3, CAMP, CNTN1, VCAM1, IL1RAP, DCD, PROZ, HGFL, MUC18, GRP78, FA5 HPT2a or HPT2a-PTM, as the biomarker, if the biomarker treatment level is less than an average measurement or range of measurements of the treatment level in the untreated population, that is also indicative that of an increased likelihood that COPD development is delayed by the pharmaceutical agent and/or the pharmaceutical agent is alleviating COPD. Assessing the level of the biomarker after the initiation of administration of the pharmaceutical agent can be performed iteratively over time to acquire additional data and thereby monitor the treatment efficacy over an extended period of time.

Airway Obstruction in COPD Patients

FEV₁ is a measure of the degree of airway obstruction. COPD of increasing severity is associated with a lower FEV₁. See Table 1. FEV₁ is measured and may be converted to a percentage of a normal FEV₁, which is based on height, weight and race. The resulting parameter is percent predicted FEV₁ (“FEV₁ (% predicted)”). For instance, an FEV₁ (% predicted) greater than 80% is considered normal (e.g., no or minimal obstruction). An FEV₁ (% predicted) of 60% to 79% is indicative of mild obstruction; 40% to 59% is indicative of moderate obstruction; and less than 40% is indicative of severe obstruction.

It has further been discovered that the plasma concentration of three biomarkers, GRP78, C163A and HGFL, is significantly correlated with the percent predicted FEV₁ in COPD patients, and that the combination of GRP78 and C163A is a robust predictor of percent predicted FEV1. Accordingly, the invention provides a method of assessing risk of COPD characterized by moderate or severe airway obstruction in a subject diagnosed with COPD. As used herein, “increased risk of COPD characterized by moderate or severe airway obstruction” refers to an increased likelihood that a COPD patient has a percent predicted FEV1 of less than 59%, such as 40% to 59% (moderate obstruction) or less than 40% (severe obstruction). The method comprises assessing the level of a biomarker from the group comprising Hepatocyte growth factor-like (HGFL); 79 kDa glucose-regulated protein (GRP78); and Scavenger receptor cysteine-rich type 1 protein M130 (C163A), in a biological fluid sample obtained from the subject. When a) an increased level of one or more of HGFL and GRP78 is assessed, relative to the level of the biomarker in a biological fluid sample from a normal reference; and/or b) a decreased level of C163A is assessed, relative to the level of the biomarker in a biological fluid sample from a normal reference, then increased risk of COPD characterized by moderate or severe airway obstruction is indicated in the subject diagnosed with COPD. The risk is proportional to the degree of increase (for HGFL and GRP78) and the degree of decrease for C163A. Therefore, the greater the increased level of HGFL, the increased level of GRP78, and/or the decreased level of C163A, the greater the risk of COPD characterized by moderate or severe airway obstruction in the subject diagnosed with COPD.

Airway obstruction in a COPD patient can be monitored as a function of time using the biomarkers. Thus, the invention further provides a method of monitoring the progression of airway obstruction in a subject diagnosed with COPD. As used herein, “progression of airway obstruction” refers to an increase in airway obstruction. The method comprises assessing the level of a biomarker from the group comprising Hepatocyte growth factor-like (HGFL); 79 kDa glucose-regulated protein (GRP78); and Scavenger receptor cysteine-rich type 1 protein M130 (C163A) in a first biological fluid sample from a subject diagnosed with COPD obtained at a first time point. The level of the biomarker is assessed in a second biological fluid sample from the subject obtained at a second time point. The level of the biomarker assessed in the first sample to the level of the biomarker detected or assessed in the second sample. If an increased level of one or more of HGFL and GRP78 is assessed in the second biological sample relative to the level in first biological fluid sample; and/or a decreased level of C163A is assessed in the second biological sample relative to the level in first biological fluid sample, then progression of airway obstruction in the subject is indicated.

In the methods relating to airway obstruction, the biological fluid may be selected from peripheral whole blood, serum and plasma. In a preferred embodiment, the biological sample is plasma. In a preferred embodiment, the levels of both GRP78 and C163A are assessed.

The methods described herein can be practiced using a single biomarker, 2 biomarkers, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or all 30 biomarkers disclosed herein. In some embodiments, the methods are practiced with at least one of HPT2a, HPT2a-PTM, GRP78, IL1RAP, and HGFL. In some embodiments, the methods are practiced with two of HPT2a, HPT2a-PTM, GRP78, IL1RAP, and HGFL. In some embodiments, the methods are practiced with all of HPT2a, HPT2a-PTM, GRP78, IL1RAP, and HGFL. In an embodiment, the methods are practiced by assessing only HPT2a, HPT2a-PTM, GRP78, IL1RAP, and HGFL. In some embodiments, at least three biomarkers, wherein each biomarker is selected from a different category, as described above. In other embodiments, the methods are practiced with at least two biomarkers selected from the same category, such as GRP78 and HGFL.

The methods of the invention can be practiced with biomarkers comprising or consisting of: HPT2a and IL1RAP; HPT2a and GRP78; HGFL and GRP78; HGFL, IL1RAP and GRP78; HPT2a, HGFL and GRP78; IL1RAP and GRP78; HPT2a, IL1RAP, and GRP78; and HPT2a, HGFL and IL1RAP, and GRP78. In an embodiment, the methods are practiced with biomarkers comprising or consisting of IL1RAP and GRP78. In another embodiment, the methods are practiced with biomarker comprising or consisting of HPT2a, IL1RAP and GRP78. In yet another embodiment, the methods are practiced with biomarkers comprising or consisting of HGFL, HPT2a, IL1RAP and GRP78.

The methods described herein rely on assessing the level of a biomarker, whose level correlates in a statistically significant manner with susceptibility to and severity of COPD, in a sample of a biological fluid obtained from the patient. The biological fluid can be selected from peripheral whole blood, and components thereof such as blood serum (“serum”) and blood plasma (“plasma”). In preferred embodiments, the biological fluid is plasma. The biological fluid is obtained from the subject using conventional methods in the art. For instance, one skilled in the art knows how to draw blood and how to process it in order to obtain serum and/or plasma for use in practicing the described methods. Generally speaking, the method of obtaining and storing, if necessary, the biological fluid sample preferably maintains the integrity of the one or more biomarkers of the disclosed herein such that it can be accurately quantified in the biological fluid sample.

The methods of the invention include quantitatively measuring the level of a protein biomarker. Methods of quantitatively assessing the level of a protein in a biological fluid such as plasma are well known in the art. In some embodiments, assessing the level of a protein involves the use of a detector molecule for the biomarker. Detector molecules can be obtained from commercial vendors or can be prepared using conventional methods in the art. Exemplary detector molecules include, but are not limited to, an antibody that binds specifically to the biomarker, a naturally-occurring cognate receptor, or functional domain thereof, for the biomarker, an aptamer that binds specifically to the biomarker, and a small molecule that binds specifically to the biomarker. Small molecules that bind specifically to a biomarker can be identified using conventional methods in the art, for instance, screening of compounds using combinatorial library methods known in the art, including biological libraries, spatially-addressable parallel solid phase or solution phase libraries, synthetic library methods requiring deconvolution, the “one-bead one-compound” library method, and synthetic library methods using affinity chromatography selection. Methods for preparing aptamers are also well-known in the art.

In a preferred embodiment, the level of a biomarker is assessed using an antibody. Thus, exemplary methods for assessing the level of a biomarker in a biological fluid sample include various immunoassays, for example, immunohistochemistry assays, immunocytochemistry assays, ELISA, capture ELISA, sandwich assays, enzyme immunoassay, radioimmunoassay, fluorescence immunoassay, and the like, all of which are known to those of skill in the art. See e.g. Harlow et al., 1988, Antibodies: A Laboratory Manual, Cold Spring Harbor, N.Y.; Harlow et al., 1999, Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, NY. Solid phase immunoassays can be particularly useful. Where two or more biomarkers are assessed, a panel of antibodies in an array format can be utilized. Custom antibody microarrays or chips can be obtained commercially.

The generation of polyclonal antibodies is accomplished by inoculating the desired animal with an antigen and isolating antibodies which specifically bind the antigen therefrom.

Monoclonal antibodies directed against one biomarkers identified herein may be prepared using any well known monoclonal antibody preparation procedures, such as those described, for example, in Harlow et al. (1988, In: Antibodies, A Laboratory Manual, Cold Spring Harbor, N.Y.) and in Tuszynski et al. (1988, Blood, 72:109-115). Human monoclonal antibodies may be prepared by the method described in U.S. patent publication 2003/0224490. Monoclonal antibodies directed against a biomarker such as GRP78 can be generated, for instance, from mice immunized with the biomarker using standard procedures as referenced herein.

For use in preparing an antibody, a biomarker may be purified from a biological source that endogenously comprises the biomarker, or from a biological source recombinantly-engineered to produce or over-produce the biomarker, using conventional methods known in the art. Exemplary protein sequences for the biomarkers are provided as SEQ ID Nos. 1-30. Exemplary nucleic acid for the biomarkers described herein are readily available in public sequence databases, such as National Library of Medicine's genetic sequence database GenBank® (Benson et al., 2008, Nucleic Acids Research, 36 (Database issue):D25-30).

Nucleic acid encoding the monoclonal antibody obtained using the procedures described herein may be cloned and sequenced using technology which is available in the art, and is described, for example, in Wright et al. (1992, Critical Rev. Immunol. 12 (3,4):125-168) and the references cited therein.

To generate a phage antibody library, a cDNA library is first obtained from mRNA which is isolated from cells, e.g., the hybridoma, which express the desired protein to be expressed on the phage surface, e.g., the desired antibody. cDNA copies of the mRNA are produced using reverse transcriptase. cDNA which specifies immunoglobulin fragments are obtained by PCR and the resulting DNA is cloned into a suitable bacteriophage vector to generate a bacteriophage DNA library comprising DNA specifying immunoglobulin genes. The procedures for making a bacteriophage library comprising heterologous DNA are well known in the art and are described, for example, in Sambrook et al. (2001, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.).

Bacteriophage which encode the desired antibody may be engineered such that the protein is displayed on the surface thereof in such a manner that it is available for binding to the antigen against which the antibody is directed. Thus, when bacteriophage which express a specific antibody are incubated in the presence of the antigen, for instance, antigen immobilized on a resin or surface, the bacteriophage will bind to the antigen. Bacteriophage which do not express the antibody will not bind to the antigen. Such panning techniques are well known in the art and are described for example, in Wright et al., (supra). Processes, such as those described above, have also been developed for the production of human antibodies using M13 bacteriophage display (Burton et al., 1994, Adv. Immunol. 57:191-280).

The procedures just presented describe the generation of phage which encode the Fab portion of an antibody molecule. However, phage which encode single chain antibodies (scFv/phage antibody libraries) are also useful in preparing Fab molecules useful in the invention. Fab molecules comprise the entire Ig light chain, that is, they comprise both the variable and constant region of the light chain, but include only the variable region and first constant region domain (CH1) of the heavy chain. Single chain antibody molecules comprise a single chain of protein comprising the Ig Fv fragment. An Ig Fv fragment includes only the variable regions of the heavy and light chains of the antibody, having no constant region contained therein. Phage libraries comprising scFv DNA may be generated following the procedures described in Marks et al., 1991, J. Mol. Biol. 222:581-597. Panning of phage so generated for the isolation of a desired antibody is conducted in a manner similar to that described for phage libraries comprising Fab DNA. Synthetic phage display libraries in which the heavy and light chain variable regions may be synthesized such that they include nearly all possible specificities (Barbas, 1995, Nature Medicine 1:837-839; de Kruif et al., 1995, J. Mol. Biol. 248:97-105) may also be used to prepare an antibody useful in the practice of the invention.

Other methods for assessing the level of a protein include chromatography (e.g., HPLC, gas chromatography, liquid chromatography) and mass spectrometry (e.g., MS, MS-MS). For instance, a chromatography medium comprising a cognate receptor for the biomarker, an aptamer that binds specifically to the biomarker, or a small molecule that binds specifically to the biomarker can be used to substantially isolate the biomarker from the sample of biological fluid.

The level of substantially isolated protein can be quantitated directly or indirectly using a conventional technique in the art such as spectrometry, Bradford protein assay, Lowry protein assay, biuret protein assay, or bicinchoninic acid protein assay, as well as immunodetection methods.

The level of a biomarker in a biological fluid sample can be normalized. For instance, the level can be normalized to another component of the fluid sample, whose level is independent of COPD susceptibility or disease severity. It is well within the skill of the skilled artisan to select a suitable component for normalization. An exemplary, but non-limiting, component for normalization is the IgG light chain.

Method of Treatment

The invention further provides a method for treatment of COPD. It is believed that GRP78 is known to provides a protective effect in lung tissue (see, e.g., Kelson et al, 2008, supra). As demonstrated herein, GRP78 is elevated in plasma of COPD patients having very severe COPD, but not in subjects that do not manifest clinical symptoms of COPD. These data suggest that in lung tissue of COPD patients, GRP78 is secreted or otherwise released from lung tissue, thereby reducing the protective effect of GRP78. Accordingly, the method for treatment of COPD comprises administering to the COPD patient one or more pharmaceutical agents that promote expression of GRP78 in lung tissue of the COPD patient. Drugs that promote expression of GRP78 are known in the art and include, but are not limited to, tunicomycin and thapsigargin. See Hara et al., 2010, Neurochem Int. 2011 January; 58(1):35-43. Epub 2010 Oct. 23.

Kits

A kit is envisaged for practicing every method disclosed herein. The following is a description of a kit useful for assessing susceptibility of developing COPD in an at-risk subject or assessing COPD severity in a COPD patient by measuring the level of a biomarker in a biological fluid. The description is not intended to be limiting and should not be construed that way.

Kits can comprise a detector molecule that binds to a biomarker of the invention. For example, the kit can comprise an antibody, an antibody derivative, or an antibody fragment that binds specifically with a biomarker protein of the invention. The kit may alternatively comprise an aptamer or small molecule that binds specifically to a biomarker of the invention. Preferably, the biomarker is selected from GRP78, HGFL, and IL1RAP. Such kits may also comprise a plurality of antibodies, antibody derivatives, or antibody fragments wherein the plurality of such antibody agents binds specifically with a biomarker protein, or a fragment of the biomarker protein.

For antibody-based kits, the kit can comprise, for example: (1) a first antibody (e.g., attached to a solid support) that binds to a biomarker; and, optionally, (2) a second, different antibody that binds to either the protein or the first antibody and is conjugated to a detectable label.

The kit can further comprise components necessary for detecting the detectable label (e.g., an enzyme or a substrate). Optionally, the kit comprises at least one negative control containing a biomarker at a concentration of about the concentration of the biomarker which is present in a biological fluid sample of a normal subject. Optionally, the kit also includes at least one positive control containing the biomarker at a concentration of about the concentration of the biomarker which is present in a biological fluid sample of a COPD patient having very severe COPD.

Furthermore, the kit can optionally include instructional material for use of the kit in the assessment of COPD susceptibility or COPD severity. Such instructions may comprise instructions to: detect the presence of or assess the level of at least one biomarker from the group comprising Lethal (3) malignant brain tumor-like 3 protein (LMBL3); Cathelicidin antimicrobial peptide (CAMP); Contactin-1 (CNTN1); Vascular cell adhesion protein 1 (VCAM1); Interleukin-1 receptor accessory protein (IL1RAP); Dermcidin (DCD); Vitamin K-dependent protein Z (PROZ); Hepatocyte growth factor-like (HGFL); Cell surface glycoprotein (MUC18); 79 kDa glucose-regulated protein (GRP78); Coagulation factor V (FA5); Scavenger receptor cysteine-rich type 1 protein M130 (C163A); Neural cell adhesion molecule (NCAM1); Proteoglycan 4 (PRG4); Procollagen C-endopeptidase enhancer 1 (PCOC1); Plastin-2 OS Homo sapiens (PLSL); Coagulation factor XIII A chain (F13A); Fetuin-B (FETUB); Protein S100-A6 (S10A); Metalloproteinase inhibitor 2 (TIMP2); Peroxiredoxin-1 (PRDX1); Macrophage colony-stimulating factor 1 receptor (CSF1R); Probable G protein coupled receptor 25 (GPR25); Putative zinc-alpha-2-glycoprotein-like 1 (ZAGL1); HLA class I histocompatibility antigen, B-15 alpha chain (1B15); Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA (MA1A1); Myelin P2 (MYP2); Metalloproteinase inhibitor 1 (TIMP1); HLA class I histocompatibility antigen, A-1 alpha chain (1A01); Haptoglobin-alpha isoform 2 (HPT2a); and HPT2a comprising one or more of four specific post-translational modifications as described herein (HPT2a-PTM), in a biological fluid sample obtained from a subject at risk of COPD or a subject diagnosed with COPD, wherein if: a) the presence of one or more of LMBL3, CAMP, CNTN1, VCAM1, IL1RAP, DCD, and PROZ is detected; b) an increased level of one or more of HGFL, MUC18, GRP78, FA5, HPT2a, and HPT2a-PTM is assessed, relative to the level of the biomarker in a biological fluid sample from a normal reference; c) a decreased level of one or more of C163A, NCAM1, PRG4, PCOC1, PLSL, F13A, and FETUB is assessed, relative to the level of the biomarker in a biological fluid sample from a normal reference; and/or d) a decreased level of one or more of S10A, TIMP2, PRDX1, CSF1R, GPR25, ZAGL1, 1B15, MA1A1, MYP2, TIMP1, and 1A01 is assessed, relative to the level of the biomarker in a biological fluid sample from a normal reference; then an increased susceptibility of developing COPD is indicated in the at-risk subject or an increased severity of COPD is indicated in the subject diagnosed with COPD.

The instructional material may comprise a publication, a recording, a diagram, or any other medium of expression which can be used to communicate the usefulness of the method of the invention in the kit for assessment of susceptibility or COPD severity in a subject. The instructional material of the kit of the invention may, for example, be affixed to a container which contains other contents of the kit, or be shipped together with a container which contains the kit. Alternatively, the instructional material may be shipped separately from the container with the intention that the instructional material and the contents of the kit be used cooperatively by the recipient.

The kit may optionally further include at least one sample container for containing a biological fluid sample obtained from the mammal Kits for practice of the invention may also comprise, e.g., buffering agents, preservatives, or protein stabilizing agents. Each component of the kit can be enclosed within an individual container and all of the various containers can be within a single package, along with instructions for interpreting the results of the assays performed using the kit.

Example

The methods and kits are further described in detail by reference to the following experimental example. The example is provided for purposes of illustration only, and is not intended to be limiting unless otherwise specified. Thus, the methods and kits should in no way be construed as being limited to the following example, but rather, should be construed to encompass any and all variations which become evident as a result of the teaching provided herein.

Study Subjects:

The plasma samples were obtained from subjects enrolled in the COPDGene® project. By design, plasma samples used in the present disclosure came from subjects similar in age, smoking history and duration of smoking cessation. Accordingly, plasma samples used in the present disclosure were obtained from phenotypically well-characterized ex-cigarette smokers 45 years of age or older with a >10 pack year exposure history. Also by design, subjects differed significantly by FEV1 and FEV1/FVC and extent of emphysema (p<0.01 for each). The following phenotypic characteristics were used to characterize subjects: spirometry, diffusion capacity, extent of emphysema (determined by chest CT scan), age, gender, ethnicity, height/weight, body mass index, 6 minute walk distance, and co-morbidities. Plasma samples from two groups of 10 subjects each were used in the present disclosure. A first group (“GOLD IV”) consisted of subjects with very severe COPD. See FIG. 1B. The second group (“GOLD 0”) consisted of subjects of ex-smokers without COPD (i.e., normal lung function). See FIG. 1A. Subjects in GOLD 0 had normal spirometry and no emphysema, in contrast to subjects in GOLD IV.

GOLD is the abbreviation for the Global Initiative for Chronic Obstructive Lung Disease. GOLD classifications designate the severity of disease for COPD patients.

A. Materials and Methods

Blood Collection:

plasma samples were obtained at the time of enrollment in the COPDGene® project. In order to optimize sample quality (i.e., minimal hemolysis and proteolysis), VACUTAINER P100 blood collection system (Beckton Dickenson, P100, Franklin Lakes, N.J.), specifically made for proteomic studies was employed. Each P100 tube can hold 7-8 mL of whole blood. Blood samples were centrifuged at room temperature within 30 minutes of collection, and the plasma aliquoted into freezer vials (500 microliter each) and stored at −80° C. until used.

Sample hemolysis was assessed from the hemoglobin concentration as determined spectrometrically. A standard hemoglobin concentration curve was constructed using a serial dilution of lysed red blood cells (RBCs). Plasma samples of each subject in both groups demonstrated similar, minimal degrees of hemolysis (less than 0.1% for each subject).

Immunodepletion of Plasma:

Plasma samples in a group were pooled together and subjected to one of two immunodepletions protocols. In one protocol, samples were immunodepleted to remove albumin and immunoglobulin by Q-proteome spin column (Qproteome Albumin/IgG Depletion Kit, Qiagen, Carson City, Calif.) in accordance with the manufacturer's instructions.

In a second protocol, samples were depleted for the 12 most abundant plasma proteins and the approximately 50 moderately abundant plasma proteins using a sequential, antibody-affinity double resin column approach in which each resin column contained a different set of bound antibodies (IgY14 spin columns and Supermix immunoaffinity chromatography columns, Sigma Inc., St. Louis, Mo.) in accordance with the manufacturer's instructions.

An aliquot of 500 microliter of pooled plasma was diluted to 2.50 milliliter (mL) in dilution buffer, filtered through a 0.45 micron spin filter and then loaded into a 5 mL column Diluted plasma samples were injected into the liquid chromatography column as 10 separate, 230 microliter injections. The eluent for each 230 microliter injection was collected from 5.00 to 19.00 min, resulting in ˜6.5 mL of immunodepleted plasma for each injection, for a total of about 65 mL diluted, immunodepleted plasma. The immunodepleted sample was immediately frozen at −80° C. Subsequently, the 65 ml of diluted, immunodepleted plasma for each group was thawed and concentrated down to 1 mL using a NANOSEP 3K spin column (Pall, Ann Arbor, Mass.) per manufacturer's protocol.

The Human IgY14 resin and Human Supermix resin antibody affinity column method of immunodepletion was more effective than the Qproteome spin column method in removing albumin and immunoglobulins. However, for both methods, the extent of immunodepletion was similar in the two study groups.

Protein Separation (1D):

Pooled samples were analyzed by gel electrophoresis-liquid chromatography mass spectroscopy (GeLC-MS) as follows.

Each of the pooled GOLD 0 and GOLD IV immunodepleted samples was diluted at a 1:2 ratio with Laemmli sample buffer (BioRad, Hercules, Calif.) containing 5% β-mercaptoethanol, heated for 10 minutes at 90° C. and loaded onto a 10-14% polyacrylamide gel. Electrophoresis was performed using a mini Protean II system (BioRad) at 200 V for 45 minutes. Separation was confirmed by staining with SimplyBlue SafeStain (Invitrogen). Each sample lanes was sliced into 20 sections, and each section further cut into ˜1 mm³ pieces in preparation for tryptic digestion.

Tryptic Digestion:

The resulting gel pieces were treated with 10 mM DTT in 50 mM ammonium bicarbonate for 30 min at 37° C., and the proteins were then alkylated with 50 mM iodoacetamide in 50 mM ammonium bicarbonate for 30 minutes at room temperature in the dark. After treatment with 50% (v/v) acetonitrile in 50 mM bicarbonate, and dehydration with pure acetonitrile, approximately 40 microliter of trypsin (12.5 microgram/microliter in 50 mM ammonium bicarbonate solution) was added to cover the gel pieces. Trypsin digestion, peptide extraction, and sample cleanup with desalting ZIPTIPS (Millipore, Billerica, Mass.) were performed as described (Duan et al., 2008, J Proteome Res. 7(11): 2438-2444).

2-DE Gel Separation and Image Analysis:

2-DE gel separation was used to study pooled samples immunodepleted by the Qproteome depletion method. The 2-DE gel separation and image analysis system employed was described previously (Kelsen et al, 2008, supra). In brief, the first dimension of separation was isoelectric focusing (IEF), which used narrow range IPG strips (pI 4-7 and 6-10). The second dimension of separation was SDS polyacrylamide gel electrophoresis. Proteins in the 2-DE gel were revealed by staining with SYPRO-Ruby fluorescent total protein stain (Molecular Probes, Eugene, Oreg.). Fluorescence images were captured and analyzed, and individual spot volumes were calculated by density/area integration and normalized for slight difference in protein loading across gels.

Protein spots were excised from the 2-DE gel and subjected to tryptic digestion as described in Kelson et al. (2008, supra) and in Boden and Merali (2011, Methods Enzymol. 2011; 489:67-82).

Identification of Differentially Expressed Proteins:

The desalted tryptic peptides were dried in a vacuum centrifuge and resolubilized in 30 microliter of 0.1% (vol/vol) trifluoroacetic acid. The tryptic peptide sample was loaded onto a 2 microgram capacity peptide trap (CapTrap™; Michrom Bioresources, Auburn, Calif.), separated by a C18 capillary column (15 cm 75 μm, Agilent) at 300 nl/min (delivered by an Agilent 1100 LC pump). A mobile-phase gradient was run using mobile phase A (1% acetonitrile/0.1% formic acid) and B (80% acetonitrile/0.1% formic acid) from 0 to 10 min with 0-15% B followed by 10-60 min with 15-60% B and 60-65 min with 60-100% B.

Nanoelectrospray ionization (ESI) tandem MS was performed using a HCT Ultra ion trap mass spectrometer (Bruker). ESI was delivered using a distal-coating spray Silica tip (ID 20 μM, tip inner ID 10 μM, New Objective) at a spray voltage of −1300 V. Using an automatic switching between MS and MS/MS modes, MS/MS fragmentation was performed on the two most abundant ions on each spectrum using collision-induced dissociation with active exclusion (excluded after two spectra, and released after 2 min) The complete system was fully controlled by HyStar 3.1 software.

Mass spectra (MS) processing was performed using Brukers Biotools (Version 2.3.0.0) with search and quantitation toolbox options. The generated de-isotoped peak list was submitted to an in-house Mascot server 2.2 for searching against the Swiss-Prot database (version 56.6 of 16 Dec. 2008, 405506 sequences). Mascot search parameters were set as follows: Homo sapiens (20413 sequences); enzyme, trypsin with maximal 1 missed cleavage; fixed modification, cysteine carbamidomethylation; variable modification, methionine oxidation; 0.50 Da mass tolerance for precursor peptide ions; and 0.6 Da for MS/MS fragment ions. All peptide matches were filtered using an ion score cutoff of 10. The following two criteria were used to evaluate protein identification: one peptide with ion score >35, two or more peptides with at least one ion score >20 (p<0.05 threshhold) and the cumulative Mascot scores >35; for all the proteins with cumulative MOWSE scores >20 and <35, the theoretical and experimental gel molecular weights had to be consistent. When these criteria were used to search against a reversed decoy Swiss-Prot database, there was no false positive match (false discovery <0.5%). For added stringency, proteins with scores above 40 were used for comparisons between samples.

Quantification of Differentially Expressed Proteins:

Mascot Distiller based label-free quantitation was used to determine the relative abundance of each identified protein in a given sample. This is quantitation based on the search results and the relative intensities of extracted ion chromatograms for precursors in both GOLD 0 and GOLD IV, aligned using mass and elution time. Distiller takes the list of peptides returned by the Mascot search and looks for the precursors in each of the survey scans. In most cases, the majority of proteins are unchanged and only a small number are significantly different.

A combination of peptide number, emPAI, sequence coverage and modified peptide counting, APEX, was also used to find out the relative abundance and determine whether given protein was differentially expressed in the COPD group relative to control; that is, either increased or decreased relative expression. Ratios whose p value was <0.05 as provided by the APEX software were accepted as statistically significantly different.

Western Blot Analysis:

Proteins (30 to 80 micrograms) from the lysates as used for the 2-DE gels were separated by 10-14% gradient SDS-PAGE. The separated proteins were transferred to a nitrocellulose membrane in a semi-dry blotting chamber according to the manufacturer's protocol (Biorad, Hercules, Calif.). Blots were blocked with 5% milk in Tris-buffer saline solution (pH 7.6) containing 0.05% Tween-20 (TBS/T), and probed with the following rabbit anti-human antibodies from Santa Cruz Biotechnology (Santa Cruz, Calif.) at a concentration of 0.4 μg/mL: GRP78, IL1RAP and HGFL. Blots were incubated with primary antibody overnight at 4° C. at with gentle shaking and then incubated with a mouse anti-rabbit HRP-conjugated secondary Ab (1:10000) (Biomeda Corp Foster City, Calif.) for 1 hr at room temperature.

Blots were exposed using a chemiluminescent detection method (Enhanced ECL Detection System, Amersham Biosciences). Gels were scanned by FLA 5100 (FujiFilm, Edison, N.J.) and the density of bands observed was determined using NIH free-ware (ImageJ software).

Statistics:

Western blots for proteins of interest were scanned and differences in band density assessed statistically by Students' t-test. Statistical significance was accepted at the p<0.05 level.

ROC Curves:

Log-ratio data were used to construct receiver operating characteristic (ROC) curves for some of the biomarkers. Since both classes, GOLD O and GOLD IV, were very small for these data, random sampling could introduce random effects that could be too big to ignore. In order to improve AUC, leave-one-out cross-validation was performed to balance the training sets by oversampling. Oversampling means that sample replicates are drawn randomly from one of the classes such that the size of that class increases. Oversampling was performed in both classes as follows. If the data comprise 11 GOLD 0 samples and 14 GOLD IV samples, then for each GOLD 0 sample, 13 replicates were added (to increase the number to 14). For each GOLD IV, 10 replicates were added (to increase number to 11). In the obtained set, both classes had the same number of samples (14*11), and any two samples from the same class had the same number of replicates.

B. Results

GeLC-MS analysis of pooled plasma samples revealed four groups of proteins having difference in expression when comparing GOLD IV to GOLD 0. The first protein group consisted of proteins whose expression level was greater (“up regulated”) in GOLD IV plasma compared to the level in GOLD 0 plasma. The data for these proteins are summarized in Table 6.

TABLE 6 Peptides Sequence Molecular MOWSE Ratio coverage emPAI Protein Name Protein ID Weight score ratio GOLD IV/GOLD 0 ratio Ratio Hepatocyte HGFL 80268 1.81 1.90 1.93 2.16 growth factor- like Cell surface MUC18 71563 2.7 3 2.4 3.5 glycoprotein 79 kDa GRP78 72288 2.76 2 2.3 2.25 glucose- regulated protein Coagulation FA5 251514 3.6 4 5 4 factor V

The second protein group consisted of proteins that were exclusively expressed in GOLD IV plasma compared to GOLD 0 plasma. The data for the proteins in this group are summarized in Table 7.

TABLE 7 Peptides Sequence Molecular MOWSE Ratio coverage emPAI Protein Name Protein ID Weight score ratio GOLD IV/GOLD 0 ratio Ratio Lethal (3) LMBL3 88280 82 2 3 0.04 malignant brain tumor-like 3 protein Cathelicidin CAMP 19289 112 2 10 0.36 antimicrobial peptide Contactin-1 CNTN1 113249 112 3 4.3 0.03 Vascular cell VCAM1 81224 120 3 4.5 0.08 adhesion protein 1 Interleukin-1 IL1RAP 65377 145 5 7 0.10 receptor accessory protein Dermcidin DCD 11277 70 1 10 0.08 Vitamin K- PROZ 44715 197 6 16.5 0.46 dependent protein Z

The third protein group consisted of proteins whose expression level was decreased (“down regulated”) in GOLD IV plasma compared to the level in GOLD 0 plasma. The data for these proteins are summarized in Table 8.

TABLE 8 Peptides Sequence Molecular MOWSE Ratio coverage emPAI Protein Name Protein ID Weight score ratio GOLD IV/GOLD 0 ratio Ratio Scavenger C163A 125355 0.37 0.25 0.25 0.25 receptor cysteine- rich type 1 protein M130 Neural cell NCAM1 94515 0.45 0.67 0.56 0.429 adhesion molecule Proteoglycan 4 PRG4 150984 0.50 0.50 0.51 0.53 Procollagen C- PCOC1 47942 0.56 0.5 0.59 0.583 endopeptidase enhancer 1 Plastin-2 OS PLSL 70245 0.57 0.57 0.89 0.74 Homo sapiens Coagulation factor F13A 83215 0.60 0.33 0.36 0.429 XIII A chain Fetuin-B FETUB 42028 0.65 0.31 0.54 0.589

The fourth protein group consisted of proteins that were exclusively expressed in GOLD 0 plasma compared to GOLD IV plasma. The data for these proteins are summarized in Table 9.

TABLE 9 Peptides Sequence Molecular MOWSE Ratio coverage emPAI Protein Name Protein ID Weight score ratio GOLD IV/GOLD 0 ratio Ratio Protein S100-A6 S10A 10173 57 2 16.7 0.32 Metalloproteinase TIMP2 24383 63 1 6.4 0.13 inhibitor 2 Peroxiredoxin-1 PRDX1 22096 64 2 10.6 0.31 Macrophage colony- CSF1R 107915 76 2 3.7 0.03 stimulating factor 1 receptor Probable G protein GPR25 38799 35 2 3.2 0.02 coupled receptor 25 Putative zinc-alpha- ZAGL1 22965 87 3 13.2 0.30 2-glycoprotein-like 1 HLA class I 1B15 40363 90 3 10.8 0.08 histocompatibility antigen, B-15 alpha chain Mannosyl- MA1A1 72922 107 4 5.8 0.09 oligosaccharide 1,2- alpha-mannosidase IA Myelin P2 MYP2 14900 112 2 13.6 0.48 Metalloproteinase TIMP1 23156 138 4 32.4 0.47 inhibitor 1 HLA class I 1A01 40820 142 3 14 0.16 histocompatibility antigen, A-1 alpha chain

The results of the proteomic analysis were validated by subjecting 10 individual samples from each GOLD group to Western blot analysis. Bands were scanned densiometrically and normalized to IgG light chain.

Data for GRP78, IL1RAP and HGFL are depicted in FIGS. 2, 3, and 4, respectively. The data are presented as box plots. The first and third quartiles are the top and bottom edges of the box area, and defines a range of values known as the “interquartile range.” The median for each data set is indicated by the center horizontal line in the box, and the mean is represented by a plus sign. The extreme values (with 1.5 times the interquartile range from the upper or lower quartile) are the ends of the lines extending from the interquartile range.

The box plots depicted in FIGS. 2, 3, and 4 exhibit little overlap of the data for GOLD IV with the data for GOLD 0. In particular, the interquartile range for GOLD IV shows virtually no overlap with the interquartile range for GOLD 0 for GRP78 and for IL1RAP. These data demonstrate the robustness of the method for identifying biomarkers distinguishing between subjects without COPD and subjects with very severe COPD. Without wishing to be bound by theory, it is believed that the robustness of the method stems in part from the very tightly matched subjects selected for the GOLD 0 and GOLD IV groups. It is further believed that this difference distinguishes these results from prior art methods and results. Moreover, these results support that each of these biomarkers can be used to assess susceptibility to COPD, assess disease severity, to monitor disease progression, and to monitor therapeutic efficacy.

2-DE gel separation was used to study pooled samples immunodepleted by the Qproteome depletion method. 2-DE gel separation represents a powerful way to examine different isoforms of the same protein and, hence, detect protein post-translational modifications. The “less immunodepleted” sample was used to assess potential differences in the highly abundant proteins that remained in the Qproteome sample.

The 2-DE gel electrophoresis data demonstrated three haptoglobin-alpha isoforms with one of these being up-regulated. See FIG. 5. The up-regulated haptoglobin-alpha isoform was identified by mass spectroscopy as the type 2 isoform of haptoglobin-alpha (designated herein as “HPT2a”). Up-regulation of HPT2a□ observed in the pooled sample was confirmed in ten individual subjects from each of the two groups. See FIG. 6A. The amount of haptoglobin-alpha isoform 2 was 3.3 fold greater (mean) in GOLD IV than GOLD 0 (FIG. 6B; p<0.02). In addition, the interquartile range for GOLD IV shows virtually no overlap with the interquartile range for GOLD 0 for HPT2a. As for GeLC-MS, these data demonstrate the robustness of the 2-DE method using immunodepleted plasma for identifying biomarkers distinguishing between subjects without COPD and subjects with very severe COPD.

Mass spectroscopy evaluation of haptoglobin-alpha isoform 2 revealed several post-translation modifications present in the GOLD IV group that were not detected in the GOLD 0 group. These modifications are: acetylation of lysine 76, carbamidomethylation of cysteine 68, and methylation of the aspartic acids at positions 71 and 72 (numbering in SEQ ID No. 12). These post-translation modifications of haptoglobin-alpha isoform 2 are unique to the GOLD IV samples and therefore, can serve as an additional discriminating marker for assessing susceptibility for COPD in an at-risk subject and severity of COPD in a COPD patient. The use of post-translation modifications as disease markers is generally known in the art (see, for instance, Karsdal et al., 2008, Clin Biochem. 2010 July; 43 (10-11):793-804. Epub 2010 Apr. 8).

Receiver operating characteristic (“ROC”) curves are graphical depictions of true positive rate versus true negative rate, and are therefore useful for assessing the accuracy of predictions. The point at (0,1) in such curves is the perfect classification: 100% sensitivity (i.e., no false negatives) and 100% specificity (i.e., no false positives). Thus, ROC curves that approach (0,1) are desirable. Area under the curve, AUC, is a useful parameter for ROC curves. Predicters are expected to have an AUC >0.5. The larger the AUC for a biomarker, the better that biomarker is expected to be as a predicter.

ROC curves were determined for four biomarkers individually and in combinations of two or three biomarker. The four biomarkers are: HPT, GRP78, IL1RAP and HGFL. The curves are depicted in FIGS. 7A, 7B and 7C. All four biomarkers have AUC values >0.5. Notably, the AUC value for GRP78 is 0.843 (FIG. 7B). In addition, combinations of two, three or all four of the biomarkers also all have AUC values >0.5. The following combinations have AUC values in excess of 0.8: HPT2a and IL1RAP (FIG. 7A); HPT2a and GRP78 (FIG. 7A); HGFL and GRP78 (FIG. 7B); HGFL, IL1RAP and GRP78 (FIG. 7A); HPT2a, HGFL and GRP78 (FIG. 7B); IL1RAP and GRP78 (FIG. 7C); HPT2a, IL1RAP, and GRP78 (FIG. 7A); and HPT2a, HGFL, IL1RAP, and GRP78 (FIG. 7C). Notably, the following combinations have AUC values in excess of 0.9: IL1RAP and GRP78; HPT2a, IL1RAP, and GRP78; and HPT2a, HGFL and IL1RAP, and GRP78.

Analysis was also performed to assess whether any of the identified biomarkers could predict the extent of FEV₁ impairment in COPD disease. FEV₁ is the maximal amount of air one can forcefully exhale in one second. The measure is converted to a percentage of normal (“FEV₁ (% predicted)”) which is a measure of the degree of obstruction, as summarized in Table 10.

TABLE 10 FEV₁ greater than 80% of predicted Normal FEV₁ 60% to 79% of predicted Mild obstruction FEV₁ 40% to 59% of predicted Moderate obstruction FEV₁ less than 40% of predicted Severe obstruction

The plasma concentration of three of the identified biomarkers, GRP78, sCD163 (which is C163A without its N-terminal signal sequence), and HGFL significantly correlated (r≧0.28; p≦0.013) with percent predicted FEV₁. See FIGS. 8A, 8B and 8D. In contrast, the plasma concentration of IL1RAP did not correlate significantly with FEV1. See FIG. 8C. Using multi-variate analysis, the combination of GRP78 and sCD163 was found to perform significantly better (r=0.46; p=0.001) than either one alone regarding percent predicted FEV₁.

The disclosures of each and every patent, patent application, and publication cited herein are hereby incorporated herein by reference in their entirety.

While the methods and kits have been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations may be devised by others skilled in the art without departing from the true spirit and scope of the described methods and kits. The appended claims are intended to be construed to include all such embodiments and equivalent variations.

TABLE 11 SwissProt Seq ID Protein Accession No. Protein Name ID No. Sequence Header info 1 Lethal (3) malignant brain tumor-like LMBL3 Q96JM7 OS = Homo sapiens 3 protein GN = L3MBTL3 PE = 1 SV = 2 2 Cathelicidin antimicrobial peptide CAMP P49913 OS = Homo sapiens GN = CAMP PE = 1 SV = 1 3 Contactin-1 CNTN1 Q12860 sp|Q12860|CNTN1_HUMAN Contactin-1 OS = Homo sapiens GN = CNTN1 PE = 1 SV = 1 4 Vascular cell adhesion protein 1 VCAM1 P19320 OS = Homo sapiens GN = VCAM1 PE = 1 SV = 1 5 Interleukin-1 receptor accessory IL1RAP Q9NPH3 OS = Homo sapiens protein GN = IL1RAP PE = 1 SV = 2 6 Dermcidin DCD P81605 OS = Homo sapiens GN = DCD PE = 1 SV = 2 7 Vitamin K-dependent protein Z PROZ P22891 OS = Homo sapiens GN = PROZ PE = 1 SV = 2 8 Hepatocyte growth factor-like HGFL P26927 OS = Homo sapiens GN = MST1 PE = 1 SV = 2 9 Cell surface glycoprotein MUC18 P43121 OS = Homo sapiens GN = MCAM PE = 1 SV = 2 10 79 kDa glucose-regulated protein GRP78 P11021 OS = Homo sapiens GN = HSPA5 PE = 1 SV = 2 11 Coagulation factor V FA5 P12259 OS = Homo sapiens GN = F5 PE = 1 SV = 4 12 Haptoglobin-alpha isoform 2 HPT2a† P00738 Residues 19-160 of P00738.1 (SEQ ID NO: 31) 13 Scavenger receptor cysteine-rich C163A Q86VB7 OS = Homo sapiens type 1 protein M130 GN = CD163 PE = 1 SV = 2 14 Neural cell adhesion molecule NCAM1 P13591 OS = Homo sapiens GN = NCAM1 PE = 1 SV = 3 15 Proteoglycan 4 PRG4 Q92954 OS = Homo sapiens GN = PRG4 PE = 1 SV = 2 16 Procollagen C-endopeptidase PCOC1 Q15133 OS = Homo sapiens enhancer 1 GN = PCOLCE PE = 1 SV = 2 17 Plastin-2 OS Homo sapiens PLSL P13796 OS = Homo sapiens GN = LCP1 PE = 1 SV = 6 18 Coagulation factor XIII A chain F13A P00488 OS = Homo sapiens GN = F13A1 PE = 1 SV = 4 19 Fetuin-B FETUB Q9UGM5 OS = Homo sapiens GN = FETUB PE = 1 SV = 2 20 Protein S100-A6 S10A P06703 OS = Homo sapiens GN = S100A6 PE = 1 SV = 1 21 Metalloproteinase inhibitor 2 TIMP2 P16035 OS = Homo sapiens GN = TIMP2 PE = 1 SV = 2 22 Peroxiredoxin-1 PRDX1 Q06830 OS = Homo sapiens GN = PRDX1 PE = 1 SV = 1 23 Macrophage colony-stimulating CSF1R P07333 OS = Homo sapiens factor 1 receptor GN = CSF1R PE = 1 SV = 2 24 Probable G protein coupled GPR25 O00155 OS = Homo sapiens receptor 25 GN = GPR25 PE = 2 SV = 2 25 Putative zinc-alpha-2-glycoprotein- ZAGL1 A8MT79 OS = Homo sapiens like 1 PE = 5 SV = 2 26 HLA class I histocompatibility 1B15 P30464 OS = Homo sapiens antigen, B-15 alpha chain GN = HLA-B PE = 1 SV = 2 27 Mannosyl-oligosaccharide1,2- MA1A1 P33908 OS = Homo sapiens alpha-mannosidase IA GN = MAN1A1 PE = 1 SV = 3 28 Myelin P2 MYP2 P02689 OS = Homo sapiens GN = PMP2 PE = 1 SV = 3 29 Metalloproteinase inhibitor 1 TIMP1 P01033 OS = Homo sapiens GN = TIMP1 PE = 1 SV = 1 30 HLA class I histocompatibility 1A01 P30443 OS = Homo sapiens antigen, A-1 alpha chain GN = HLA-A PE = 1 SV = 1 31 Haptoglobin-alpha isoform 2 HPT2 P00738 Signal sequence: residues 1-18 preproprotein Haptoglobin alpha: residues 19-160 Haptoglobin beta: residues 162-406 32 Haptoglobin-alpha isoform 2 having a HPT2a- n/a Peptide sequence within SEQ post-translational modification PTM ID No. 12 in which post- translational modifications (PTMs) uniquely present in GOLD IV subjects; PTMs are: C1 = carbamidomethylation; D4 = methylation; D5 = methylation; K9 = acetylation 

1. (canceled)
 2. A method of treating chronic obstructive pulmonary disease (COPD) in a subject in need of such treatment, the method comprising: (a) determining the level of at least 79 kDa glucose-regulated protein (GRP78) in a biological fluid sample from the subject selected from peripheral whole blood, serum and plasma; (b) comparing the level of GRP78 in the test sample with the level of GRP78 in a normal reference sample; (c) determining an elevated level of GRP78 in the test sample as compared to the level of GRP78 in the control sample; (d) administering a treatment to the subject comprising one or more pharmaceutical agents that promote the expression of GRP78 in lung tissue.
 3. The method according to claim 2 wherein the biological fluid sample is serum or plasma.
 4. The method according to claim 2 wherein the reference sample is from an individual that does not manifest clinical symptoms of COPD.
 5. The method according to claim 2 wherein the pharmaceutical agent is tunicomycin.
 6. The method according to claim 2 wherein the pharmaceutical agent is thapsigargin.
 7. A method of treating COPD comprising: administering a COPD treatment to a subject in which a biological fluid test sample from the subject selected from peripheral whole blood, serum and plasma has been determined to contain an elevated level of 79 kDa glucose-regulated protein (GRP78), compared to the level of GRP78 in a normal reference sample, said COPD treatment comprising one or more pharmaceutical agents that promote the expression of GRP78 in lung tissue; said COPD.
 8. The method according to claim 7 wherein the biological fluid sample is serum or plasma.
 9. The method according to claim 7 wherein the reference sample is from an individual that does not manifest clinical symptoms of COPD.
 10. The method according to claim 7 wherein the pharmaceutical agent is tunicomycin.
 11. The method according to claim 7 wherein the pharmaceutical agent is thapsigargin. 